Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 119,700 shares, an increase of 93.4% from the February 13th total of 61,900 shares. Currently, 6.5% of the shares of the stock are sold short. Based on an average daily volume of 4,130,000 shares, the days-to-cover ratio is currently 0.0 days.

Cyclerion Therapeutics Stock Performance

Cyclerion Therapeutics stock traded up $0.06 on Friday, reaching $2.53. The company’s stock had a trading volume of 7,764 shares, compared to its average volume of 2,412,826. Cyclerion Therapeutics has a twelve month low of $1.27 and a twelve month high of $9.47. The company has a market cap of $6.86 million, a price-to-earnings ratio of -2.07 and a beta of 2.09. The business’s fifty day moving average price is $3.05 and its 200 day moving average price is $2.90.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $1.81 million for the quarter.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Renaissance Technologies LLC bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.39% of Cyclerion Therapeutics at the end of the most recent quarter. Institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.